<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Ophthalmol</journal-id><journal-id journal-id-type="publisher-id">Indian Journal of Ophthalmology</journal-id><journal-title-group><journal-title>Indian Journal of Ophthalmology</journal-title></journal-title-group><issn pub-type="ppub">0301-4738</issn><issn pub-type="epub">1998-3689</issn><publisher><publisher-name>Medknow Publications</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">18711282</article-id><article-id pub-id-type="pmc">2636151</article-id><article-id pub-id-type="publisher-id">IndianJOphthalmol_2008_56_5_438_42430</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter to the Editor</subject></subj-group></article-categories><title-group><article-title>Combined photodynamic therapyand intravitreal ranibizumab asprimary treatment for choroidalneovascularization associated withage-related macular degeneration inan Indian patient</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Rishi</surname><given-names>Pukhraj</given-names></name><degrees>MS</degrees></contrib><contrib contrib-type="author"><name><surname>Sen</surname><given-names>Pratik Ranjan</given-names></name><degrees>MS</degrees></contrib><contrib contrib-type="author"><name><surname>Shroff</surname><given-names>Daraius</given-names></name><degrees>MS</degrees></contrib><contrib contrib-type="author"><name><surname>Chhablani</surname><given-names>Jay</given-names></name><degrees>MS</degrees></contrib></contrib-group><aff>Shri Bhagwan Mahavir Vitreretinal Services, Sankara Nethralaya,18, College Road, Chennai - 600 006, Tamil Nadu, India</aff><author-notes><corresp id="cor1">Correspondence to Dr. Pukhraj Rishi, Sankara Nethralaya,18, College Road, Chennai - 600 006, Tamil Nadu, India.Email: <email>docrishi@yahoo.co.in</email></corresp></author-notes><pub-date pub-type="ppub"><season>Sep-Oct</season><year>2008</year></pub-date><volume>56</volume><issue>5</issue><fpage>438</fpage><lpage>439</lpage><permissions><copyright-statement>Copyright: &#x000a9; Indian Journal of Ophthalmology</copyright-statement><copyright-year>2008</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work isproperly cited.</license-p></license></permissions></article-meta></front><body><p>Dear Editor,</p><p>We report the efficacy of combination therapy usingphotodynamic therapy (PDT) and intravitreal ranibizumabfor choroidal neovascular membrane (CNVM) associated withage-related macular degeneration (ARMD) in an Indian patient,for the first time.</p><p>A 65-year-old lady presented with decreased vision inthe left eye since four weeks. Right eye was phthisical withno perception of light. Vision was 20/80 in the left eye.Biomicroscopic evaluation of the anterior segment wasunremarkable except for early cataractous changes. Fundusexamination revealed an extrafoveal CNVM underlying thepapillomacular bundle [Figure <xref ref-type="fig" rid="F1A">1A</xref>]. Clinical findings werecorroborated on fundus fluorescein angiography (FFA) [Figure<xref ref-type="fig" rid="F1B">1B</xref>] and optical coherence tomography (OCT) [Figure <xref ref-type="fig" rid="F1C">1C</xref>].Considering the location of the CNVM and the single-eyedstatus of the patient, laser photocoagulation was thought tobe best avoided. The patient underwent PDT as per standardprotocol followed by intravitreal ranibizumab (0.5 mg), twodays later. No treatment-related adverse effect was noted. At16 weeks follow-up, visual acuity improved to 20/20. Clinicalexamination revealed regression of CNVM with no evidenceof subretinal fluid. Clinical findings were confirmed on OCTwhich revealed a scarred CNVM with restoration of the retinalthickness and foveal contour <xref ref-type="fig" rid="F2">Figure 2</xref>. The fundus remainedstable and visual acuity was maintained at the sixth monthfollow-up.</p><p>Ranibizumab (Lucentis, Genetech, Inc, South San Francisco,California, USA) is an FDA-approved monoclonal antibodyfragment that targets all vascular endothelial growth factor(VEGF)-A isoforms.<xref ref-type="bibr" rid="ref1">1</xref> Combined treatment using PDT andbevacizumab has been shown to be effective in improvingvisual acuity and decreasing retreatment rates in choroidalneovascularization (CNV) associated with ARMD.<xref ref-type="bibr" rid="ref2">2</xref> Thecombined regime is postulated to have a beneficial synergisticeffect that could reduce the need for cyclic injections.<xref ref-type="bibr" rid="ref2">2</xref>,<xref ref-type="bibr" rid="ref3">3</xref></p><p>Combination therapy using ranibizumab and PDT hasbeen reported previously in a single clinical trial in theWestern literature, where the combination was found to bemore efficacious than PDT alone.<xref ref-type="bibr" rid="ref4">4</xref> VEGF inhibition alonecould prevent neovascularization at an early developmentalstage. However, once neovascular beds are established theyare unlikely to regress with anti-VEGF therapy alone.<xref ref-type="bibr" rid="ref3">3</xref> At thisstage, a combined approach using a non-thermal laser has beenseen to be beneficial. Since it is still unknown as to which stageCNV would become unresponsive to VEGF inhibition alone,combination therapy treatment using PDT and ranibizumabas the first-line management in such cases could be a viableoption.</p></body><back><ref-list><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenfeld</surname><given-names>PJ</given-names></name><name><surname>Rich</surname><given-names>RM</given-names></name><name><surname>Lalwani</surname><given-names>G</given-names></name></person-group><article-title>Ranibizumab: Phase III clinical trial results</article-title><source>Ophthalmol Clin North Am</source><year>2006</year><volume>19</volume><fpage>361</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">16935211</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spaide</surname><given-names>RF</given-names></name></person-group><article-title>Rationale for combination therapies for choroidalneovascularization</article-title><source>Am J Ophthalmol</source><year>2006</year><volume>141</volume><fpage>149</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">16386991</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhalla</surname><given-names>MS</given-names></name><name><surname>Shah</surname><given-names>GK</given-names></name><name><surname>Blinder</surname><given-names>KJ</given-names></name><name><surname>Ryan</surname><given-names>EH</given-names><suffix>Jr</suffix></name><name><surname>Mittra</surname><given-names>RA</given-names></name><name><surname>Tewari</surname><given-names>A</given-names></name></person-group><article-title>Combined photodynamic therapy with verteporfin and intravitrealbevacizumab for choroidal neovascularization in age-relatedmacular degeneration</article-title><source>Retina</source><year>2006</year><volume>26</volume><fpage>988</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">17151484</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heier</surname><given-names>JS</given-names></name><name><surname>Boyer</surname><given-names>DS</given-names></name><name><surname>Ciulla</surname><given-names>TA</given-names></name><name><surname>Ferrone</surname><given-names>PJ</given-names></name><name><surname>Jumper</surname><given-names>JM</given-names></name><name><surname>Gentile</surname><given-names>RC</given-names></name><etal/></person-group><article-title>Ranibizumab combined with verteporfin photodynamictherapy in neovascular age-related macular degeneration: Year 1results of the FOCUS Study</article-title><source>Arch Ophthalmol</source><year>2006</year><volume>124</volume><fpage>1532</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">17101999</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1A" position="float"><label>Figure 1A</label><caption><p>(A) Color fundus photograph of the left eye reveals a choroidalneovascular membrane underlying the papillomacular bundle. Hardexudates and subretinal hemorrhages are noted surrounding it.</p></caption><alt-text>Figure 1A</alt-text><graphic xlink:href="IndianJOphthalmol-56-438-g001"/></fig><fig id="F1B" position="float"><label>Figure 1B</label><caption><p>(B) Fundus fluorescein angiography reveals the presence of leakage fromthe lesion characteristic of a classic choroidal neovascular membrane.</p></caption><alt-text>Figure 1B</alt-text><graphic xlink:href="IndianJOphthalmol-56-438-g002"/></fig><fig id="F1C" position="float"><label>Figure 1C</label><caption><p>(C) Optical coherence tomography reveals the presence of a choroidalneovascular membrane with subfoveal fluid</p></caption><alt-text>Figure 1C</alt-text><graphic xlink:href="IndianJOphthalmol-56-438-g003"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><p>Optical coherence tomography reveals the presence of ascarred choroidal neovascular membrane with restoration of retinalthickness and foveal contour</p></caption><alt-text>Figure 2</alt-text><graphic xlink:href="IndianJOphthalmol-56-438-g004"/></fig></floats-group></article>